Current Cancer Drug Targets
Volume 20, 11 Issues, 2020
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
Ranking and Category
-
135th of 229 in
Oncology
  |
In the current Pandemic scenario, all articles related to Coronavirus will be processed on a free, quick track basis, to ensure timely review and publication of much needed research
Contents
Current Cancer Drug Targets, Volume 18 - Number 2
Biography
Editorial
Review Article
Oncolytic Viruses: The Best is Yet to Come
, 18(2): 109 - 123Chantal G. Lemay, Brian A. Keller, Robert E. Edge, Masato Abei and John C. Bell*
DOI: 10.2174/1568009617666170206111609
Oncolytic Viruses: The Best is Yet to Come
Review Article
Cancer-Targeted Oncolytic Adenoviruses for Modulation of the Immune System
, 18(2): 124 - 138Vincenzo Cerullo*, Cristian Capasso, Markus Vaha-Koskela, Otto Hemminki and Akseli Hemminki*
DOI: 10.2174/1568009617666170502152352
Cancer-Targeted Oncolytic Adenoviruses for Modulation of the Immune System
Review Article
Emergence of Ad-Mediated Combination Therapy Against Cancer: What to Expect?
, 18(2): 139 - 152JinWoo Hong and Chae-Ok Yun*
DOI: 10.2174/1568009617666170222123406
Emergence of Ad-Mediated Combination Therapy Against Cancer: What to Expect?
Review Article
The Development of Oncoltyic Adenovirus Therapy in the Past and Future - For the Case of Pancreatic Cancer
, 18(2): 153 - 161Mizuho Sato-Dahlman and Masato Yamamoto*
DOI: 10.2174/1568009617666170222123925
The Development of Oncoltyic Adenovirus Therapy in the Past and Future - For the Case of Pancreatic Cancer
Review Article
Oncolytic Herpes Simplex Virus Vectors Fully Retargeted to Tumor- Associated Antigens
, 18(2): 162 - 170Hiroaki Uchida*, Hirofumi Hamada, Kenji Nakano, Heechung Kwon, Hideaki Tahara, Justus B. Cohen and Joseph C. Glorioso
DOI: 10.2174/1568009617666170206105855
Oncolytic Herpes Simplex Virus Vectors Fully Retargeted to Tumor- Associated Antigens
Review Article
Oncorine, the World First Oncolytic Virus Medicine and its Update in China
, 18(2): 171 - 176Min Liang*
DOI: 10.2174/1568009618666171129221503
Oncorine, the World First Oncolytic Virus Medicine and its Update in China
Review Article
Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects
, 18(2): 177 - 187Pavlos Msaouel, Mateusz Opyrchal, Angela Dispenzieri, Kah Whye Peng, Mark J. Federspiel, Stephen J. Russell and Evanthia Galanis*
DOI: 10.2174/1568009617666170222125035
Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects
Review Article
Oncolytic Virotherapy and Gene Therapy Strategies for Hepatobiliary Cancers
, 18(2): 188 - 201Takeshi Yamada, Yukako Hamano, Naoyuki Hasegawa, Emiko Seo, Kuniaki Fukuda, Kazunari K. Yokoyama*, Ichinosuke Hyodo and Masato Abei*
DOI: 10.2174/1568009617666170330123841
Oncolytic Virotherapy and Gene Therapy Strategies for Hepatobiliary Cancers
Review Article
Oncolytic Virus: Regulatory Aspects from Quality Control to Clinical Studies
, 18(2): 202 - 208Teruhide Yamaguchi* and Eriko Uchida
DOI: 10.2174/1568009617666170222142650
Oncolytic Virus: Regulatory Aspects from Quality Control to Clinical Studies
Research Article
TGF-β1 Causes EMT by Regulating N-Acetyl Glucosaminyl Transferases via Downregulation of Non Muscle Myosin II-A through JNK/P38/PI3K Pathway in Lung Cancer
, 18(2): 209 - 219Ghulam Jilany Khan, Yingsheng Gao, Ming Gu, Lai Wang, Sara Khan, Farah Naeem, Herve Semukunzi, Debmalya Roy, Shengtao Yuan* and Li Sun*
DOI: 10.2174/1568009617666170807120304
TGF-β1 Causes EMT by Regulating N-Acetyl Glucosaminyl Transferases via Downregulation of Non Muscle Myosin II-A through JNK/P38/PI3K Pathway in Lung Cancer
Editor-in-Chief
Ruiwen Zhang
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204
(USA)
View Full Editorial Board
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204
View Full Editorial Board
About the Journal
For Authors
For Librarians & Readers
Quick Links
Journal History
Current Cancer Drug Targets was launched in 2001. Dr. Ruiwen Zhang serves as the Editor-in-Chief of the journal.
Scopus CiteScore Metrics: 2.75
Advertisement
Webmaster Contact: info@benthamscience.net